Cross-source evidence timeline

Daptomycin research timeline

Follow 102 selected, directly cited source records from September 12, 2003 through November 9, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

102Selected records
17Source years
3Evidence lanes
November 9, 2026Latest source date

Source year

2026

9 records
  1. Literature metadata

    Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.↗

    PubMed lists PMID 32725216 in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Equivalence Trial, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks.↗

    PubMed lists PMID 42869054 in The Lancet. Infectious diseases as Journal Article, Review, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Clinical Pharmacokinetics of Daptomycin.↗

    PubMed lists PMID 33313994 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    The Antibiotic Peptide Daptomycin Functions by Reorganizing the Membrane.↗

    PubMed lists PMID 33620544 in The Journal of membrane biology as Journal Article, Review, with publication-date metadata of 2021-02-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT03138733↗

    PeptideScanner retained ClinicalTrials.gov record NCT03138733 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT07148960↗

    PeptideScanner retained ClinicalTrials.gov record NCT07148960 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT05137119↗

    PeptideScanner retained ClinicalTrials.gov record NCT05137119 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT04983901↗

    PeptideScanner retained ClinicalTrials.gov record NCT04983901 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  9. Literature metadata

    Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin.↗

    PubMed lists PMID 41297715 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

7 records
  1. Literature metadata

    Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations.↗

    PubMed lists PMID 41321327 in Critical reviews in analytical chemistry as Journal Article, Review, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series.↗

    PubMed lists PMID 39028390 in Infection as Systematic Review, Journal Article, Case Reports, with publication-date metadata of 2024-07-19 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Use of Daptomycin to Manage Severe MRSA Infections in Humans.↗

    PubMed lists PMID 40558207 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-06-18 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-a…↗

    PubMed lists PMID 32321574 in Antimicrobial resistance and infection control as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-04-22 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review.↗

    PubMed lists PMID 39216593 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Case Reports, Review, with publication-date metadata of 2024-08-30 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Regulatory

    Federal Register notice 2025-06048↗

    The Federal Register published notice 2025-06048, attributed to FDA and its parent HHS department, on 2025-04-09. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

  7. Literature metadata

    Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections.↗

    PubMed lists PMID 39896981 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2025-01-17 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

6 records
  1. Literature metadata

    Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review.↗

    PubMed lists PMID 38606836 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, Case Reports, with publication-date metadata of 2024-04-12 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT04775953↗

    PeptideScanner retained ClinicalTrials.gov record NCT04775953 at 2026-11-15T22:01:45.056Z. Its registry update date was 2024-12-10, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  3. Regulatory

    Drugs@FDA application NDA217630↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 217630 with status AP dated 2024-11-21, and names daptomycin among the application record's active ingredients.↗

  4. Regulatory

    Drugs@FDA application ANDA217215↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 217215 with status AP dated 2024-08-29, and names daptomycin among the application record's active ingredients.↗

  5. Regulatory

    Drugs@FDA application ANDA213396↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213396 with status AP dated 2024-08-01, and names daptomycin among the application record's active ingredients.↗

  6. Literature metadata

    Daptomycin as an option for lock therapy: a systematic literature review.↗

    PubMed lists PMID 37622290 in Future microbiology as Journal Article, Systematic Review, with publication-date metadata of 2023-08-25 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

8 records
  1. Regulatory

    Federal Register notice 2023-24120↗

    The Federal Register published notice 2023-24120, attributed to FDA and its parent HHS department, on 2023-11-01. Its official title is “Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03426761↗

    PeptideScanner retained ClinicalTrials.gov record NCT03426761 at 2026-11-15T22:01:45.056Z. Its registry update date was 2023-10-03, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  3. Regulatory

    Drugs@FDA application ANDA213966↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213966 with status AP dated 2023-08-07, and names daptomycin among the application record's active ingredients.↗

  4. Regulatory

    Federal Register notice 2023-16775↗

    The Federal Register published notice 2023-16775, attributed to FDA and its parent HHS department, on 2023-08-07. Its official title is “Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

  5. Literature metadata

    Daptomycin for the treatment of acute bacterial meningitis: A narrative review.↗

    PubMed lists PMID 36870402 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2023-03-02 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Bacterial cell membranes and their role in daptomycin resistance: A review.↗

    PubMed lists PMID 36452455 in Frontiers in molecular biosciences as Journal Article, Review, with publication-date metadata of 2022-11-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.↗

    PubMed lists PMID 36227704 in The Journal of antimicrobial chemotherapy as Systematic Review, Journal Article, with publication-date metadata of 2022-12-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Regulatory

    Drugs@FDA application NDA217415↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 217415 with status AP dated 2023-01-30, and names daptomycin among the application record's active ingredients.↗

Source year

2022

8 records
  1. Regulatory

    Drugs@FDA application ANDA216445↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 216445 with status AP dated 2022-12-23, and names daptomycin among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA216413↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 216413 with status AP dated 2022-09-23, and names daptomycin among the application record's active ingredients.↗

  3. Literature metadata

    Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.↗

    PubMed lists PMID 31207214 in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases as Journal Article, Systematic Review, with publication-date metadata of 2019-06-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Drugs@FDA application ANDA215890↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 215890 with status AP dated 2022-08-18, and names daptomycin among the application record's active ingredients.↗

  5. Literature metadata

    Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant Staphylococcus aureus: A Network…↗

    PubMed lists PMID 35656305 in Frontiers in pharmacology as Systematic Review, Journal Article, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM.↗

    PubMed lists PMID 35786589 in Biological & pharmaceutical bulletin as Journal Article, Meta-Analysis, with publication-date metadata of 2022 (year precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Regulatory

    Federal Register notice 2022-01693↗

    The Federal Register published notice 2022-01693, attributed to FDA and its parent HHS department, on 2022-01-28. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

  8. Regulatory

    Drugs@FDA application NDA213645↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 213645 with status AP dated 2022-01-25, and names daptomycin among the application record's active ingredients.↗

Source year

2021

16 records
  1. Literature metadata

    What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant Staphylococcus aureus bacteraemia? A review.↗

    PubMed lists PMID 33563707 in Postgraduate medical journal as Journal Article, Review, with publication-date metadata of 2021-02-09 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-Analysis.↗

    PubMed lists PMID 33728980 in Microbial drug resistance (Larchmont, N.Y.) as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2021-03-15 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Regulatory

    Drugs@FDA application ANDA215215↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 215215 with status AP dated 2021-11-26, and names daptomycin among the application record's active ingredients.↗

  4. Regulatory

    Federal Register notice 2021-25111↗

    The Federal Register published notice 2021-25111, attributed to FDA and its parent HHS department, on 2021-11-18. Its official title is “Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin and Eptifibatide.↗

  5. Literature metadata

    The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Strains From Human Clinical Samples: A Systematic Review and Meta-Analysis.↗

    PubMed lists PMID 34568377 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2021-09-10 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Regulatory

    Drugs@FDA application ANDA213171↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213171 with status AP dated 2021-09-02, and names daptomycin among the application record's active ingredients.↗

  7. Literature metadata

    Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis.↗

    PubMed lists PMID 34439067 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-08-21 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Regulatory

    Drugs@FDA application ANDA215316↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 215316 with status AP dated 2021-08-24, and names daptomycin among the application record's active ingredients.↗

  9. Regulatory

    Drugs@FDA application ANDA213623↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213623 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients.↗

  10. Regulatory

    Drugs@FDA application ANDA213786↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213786 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients.↗

  11. Regulatory

    Drugs@FDA application NDA210282↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 210282 with status AP dated 2021-06-21, and names daptomycin among the application record's active ingredients.↗

  12. Literature metadata

    Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis.↗

    PubMed lists PMID 32839217 in Antimicrobial agents and chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-10-20 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  13. Literature metadata

    Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis.↗

    PubMed lists PMID 32533859 in Pharmacotherapy as Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, with publication-date metadata of 2020-07-06 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  14. Regulatory

    Drugs@FDA application ANDA212250↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212250 with status AP dated 2021-04-21, and names daptomycin among the application record's active ingredients.↗

  15. Clinical trials

    ClinicalTrials.gov record NCT00467272↗

    PeptideScanner retained ClinicalTrials.gov record NCT00467272 at 2026-11-15T22:01:45.056Z. Its registry update date was 2021-02-08, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  16. Literature metadata

    DAPTOMYCIN, its membrane-active mechanism vs. that of other antimicrobial peptides.↗

    PubMed lists PMID 32526177 in Biochimica et biophysica acta. Biomembranes as Journal Article, Research Support, N.I.H., Extramural, Review, with publication-date metadata of 2020-06-09 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

7 records
  1. Literature metadata

    Treatment Considerations for CNS Infections Caused by Vancomycin-Resistant Enterococcus faecium: A Focused Review of Linezolid and Daptomycin.↗

    PubMed lists PMID 32506921 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2020-06-08 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Regulatory

    Federal Register notice 2020-23439↗

    The Federal Register published notice 2020-23439, attributed to FDA and its parent HHS department, on 2020-10-22. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT02972983↗

    PeptideScanner retained ClinicalTrials.gov record NCT02972983 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-09-22, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  4. Regulatory

    Drugs@FDA application ANDA211403↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 211403 with status AP dated 2020-08-31, and names daptomycin among the application record's active ingredients.↗

  5. Regulatory

    Drugs@FDA application ANDA213425↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213425 with status AP dated 2020-08-20, and names daptomycin among the application record's active ingredients.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT01792804↗

    PeptideScanner retained ClinicalTrials.gov record NCT01792804 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-05-27, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  7. Literature metadata

    Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia.↗

    PubMed lists PMID 31284042 in International journal of antimicrobial agents as Journal Article, Meta-Analysis, with publication-date metadata of 2019-07-05 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2019

12 records
  1. Literature metadata

    MprF-mediated daptomycin resistance.↗

    PubMed lists PMID 31182276 in International journal of medical microbiology : IJMM as Journal Article, Review, with publication-date metadata of 2019-06-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Regulatory

    Drugs@FDA application ANDA207104↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 207104 with status AP dated 2019-11-15, and names daptomycin among the application record's active ingredients.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00538694↗

    PeptideScanner retained ClinicalTrials.gov record NCT00538694 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00540072↗

    PeptideScanner retained ClinicalTrials.gov record NCT00540072 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  5. Literature metadata

    Bone penetration of daptomycin in diabetic patients with bacterial foot infections.↗

    PubMed lists PMID 31096056 in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases as Clinical Trial, Journal Article, with publication-date metadata of 2019-05-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Regulatory

    Drugs@FDA application ANDA212022↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212022 with status AP dated 2019-08-22, and names daptomycin among the application record's active ingredients.↗

  7. Regulatory

    Drugs@FDA application ANDA212667↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212667 with status AP dated 2019-07-12, and names daptomycin among the application record's active ingredients.↗

  8. Regulatory

    Drugs@FDA application ANDA212513↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212513 with status AP dated 2019-06-26, and names daptomycin among the application record's active ingredients.↗

  9. Regulatory

    Drugs@FDA application ANDA211961↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 211961 with status AP dated 2019-06-24, and names daptomycin among the application record's active ingredients.↗

  10. Regulatory

    Drugs@FDA application ANDA208375↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 208375 with status AP dated 2019-05-01, and names daptomycin among the application record's active ingredients.↗

  11. Regulatory

    Federal Register notice 2019-06385↗

    The Federal Register published notice 2019-06385, attributed to FDA and its parent HHS department, on 2019-04-02. Its official title is “Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

  12. Regulatory

    Federal Register notice 2019-03129↗

    The Federal Register published notice 2019-03129, attributed to FDA and its parent HHS department, on 2019-02-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

Source year

2018

11 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00711802↗

    PeptideScanner retained ClinicalTrials.gov record NCT00711802 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01419184↗

    PeptideScanner retained ClinicalTrials.gov record NCT01419184 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01728376↗

    PeptideScanner retained ClinicalTrials.gov record NCT01728376 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT01922011↗

    PeptideScanner retained ClinicalTrials.gov record NCT01922011 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01012089↗

    PeptideScanner retained ClinicalTrials.gov record NCT01012089 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-06-06, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  6. Regulatory

    Drugs@FDA application ANDA205037↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 205037 with status AP dated 2018-06-05, and names daptomycin among the application record's active ingredients.↗

  7. Regulatory

    Drugs@FDA application ANDA206077↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 206077 with status AP dated 2018-04-11, and names daptomycin among the application record's active ingredients.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT00882557↗

    PeptideScanner retained ClinicalTrials.gov record NCT00882557 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT02660346↗

    PeptideScanner retained ClinicalTrials.gov record NCT02660346 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-01, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT00428844↗

    PeptideScanner retained ClinicalTrials.gov record NCT00428844 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-31, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT01191840↗

    PeptideScanner retained ClinicalTrials.gov record NCT01191840 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-05, and PeptideScanner's reviewed identity mapping was daptomycin.↗

Source year

2017

4 records
  1. Regulatory

    Drugs@FDA application NDA209949↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 209949 with status AP dated 2017-10-20, and names daptomycin among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application NDA208385↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 208385 with status AP dated 2017-09-12, and names daptomycin among the application record's active ingredients.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00295178↗

    PeptideScanner retained ClinicalTrials.gov record NCT00295178 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-09-07, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00093067↗

    PeptideScanner retained ClinicalTrials.gov record NCT00093067 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-02-13, and PeptideScanner's reviewed identity mapping was daptomycin.↗

Source year

2016

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00701636↗

    PeptideScanner retained ClinicalTrials.gov record NCT00701636 at 2026-11-15T22:01:45.056Z. Its registry update date was 2016-08-29, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  2. Regulatory

    Drugs@FDA application ANDA206005↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 206005 with status AP dated 2016-06-15, and names daptomycin among the application record's active ingredients.↗

  3. Regulatory

    Drugs@FDA application ANDA091039↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 091039 with status AP dated 2016-03-25, and names daptomycin among the application record's active ingredients.↗

Source year

2015

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00663403↗

    PeptideScanner retained ClinicalTrials.gov record NCT00663403 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-12-30, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01626560↗

    PeptideScanner retained ClinicalTrials.gov record NCT01626560 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00772447↗

    PeptideScanner retained ClinicalTrials.gov record NCT00772447 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-09, and PeptideScanner's reviewed identity mapping was daptomycin.↗

Source year

2014

2 records
  1. Regulatory

    Drugs@FDA application ANDA202857↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 202857 with status AP dated 2014-09-12, and names daptomycin among the application record's active ingredients.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01549613↗

    PeptideScanner retained ClinicalTrials.gov record NCT01549613 at 2026-11-15T22:01:45.056Z. Its registry update date was 2014-08-01, and PeptideScanner's reviewed identity mapping was daptomycin.↗

Source year

2013

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00942149↗

    PeptideScanner retained ClinicalTrials.gov record NCT00942149 at 2026-11-15T22:01:45.056Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was daptomycin.↗

Source year

2012

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01184872↗

    PeptideScanner retained ClinicalTrials.gov record NCT01184872 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-07-13, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01080963↗

    PeptideScanner retained ClinicalTrials.gov record NCT01080963 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-04-17, and PeptideScanner's reviewed identity mapping was daptomycin.↗

Source year

2006

2 records
  1. Regulatory

    Federal Register notice E6-9225↗

    The Federal Register published notice E6-9225, attributed to FDA and its parent HHS department, on 2006-06-14. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

  2. Regulatory

    Federal Register notice E6-1069↗

    The Federal Register published notice E6-1069, attributed to FDA and its parent HHS department, on 2006-01-30. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.↗

Source year

2003

1 record
  1. Regulatory

    Drugs@FDA application NDA021572↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 021572 with status AP dated 2003-09-12, and names daptomycin among the application record's active ingredients.↗